Pamela Zeitlin
Concepts (471)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cystic Fibrosis Transmembrane Conductance Regulator | 44 | 2022 | 287 | 7.220 |
Why?
| Cystic Fibrosis | 67 | 2022 | 953 | 6.470 |
Why?
| Chlorides | 11 | 2020 | 130 | 1.590 |
Why?
| Chloride Channels | 11 | 2013 | 35 | 1.510 |
Why?
| Benzodioxoles | 6 | 2022 | 83 | 1.240 |
Why?
| Bronchi | 9 | 2012 | 222 | 1.120 |
Why?
| Epithelial Cells | 12 | 2021 | 939 | 1.110 |
Why?
| Mutation | 17 | 2022 | 3313 | 1.070 |
Why?
| Nasal Mucosa | 10 | 2020 | 93 | 0.930 |
Why?
| Interleukin-8 | 8 | 2017 | 230 | 0.870 |
Why?
| Indoles | 3 | 2022 | 296 | 0.810 |
Why?
| Phenylbutyrates | 4 | 2006 | 21 | 0.750 |
Why?
| Alprostadil | 2 | 2013 | 31 | 0.730 |
Why?
| Aminophenols | 6 | 2022 | 112 | 0.700 |
Why?
| Respiratory Mucosa | 7 | 2008 | 251 | 0.650 |
Why?
| Genetic Therapy | 8 | 2011 | 253 | 0.600 |
Why?
| Dependovirus | 5 | 2007 | 50 | 0.600 |
Why?
| Pseudomonas Infections | 5 | 2020 | 183 | 0.580 |
Why?
| Endoplasmic Reticulum | 8 | 2014 | 233 | 0.570 |
Why?
| Digitoxin | 1 | 2017 | 3 | 0.560 |
Why?
| Proteomics | 3 | 2012 | 808 | 0.540 |
Why?
| Protein Processing, Post-Translational | 3 | 2014 | 394 | 0.540 |
Why?
| Epithelium | 4 | 2021 | 293 | 0.540 |
Why?
| Ubiquitin | 2 | 2014 | 57 | 0.540 |
Why?
| Lung | 10 | 2022 | 3497 | 0.530 |
Why?
| Mucociliary Clearance | 3 | 2021 | 42 | 0.510 |
Why?
| Proteasome Endopeptidase Complex | 3 | 2014 | 132 | 0.500 |
Why?
| Sputum | 10 | 2020 | 284 | 0.490 |
Why?
| Anti-Inflammatory Agents | 2 | 2017 | 442 | 0.470 |
Why?
| Sp1 Transcription Factor | 2 | 2006 | 23 | 0.470 |
Why?
| Ion Transport | 5 | 2020 | 54 | 0.430 |
Why?
| Scorpion Venoms | 1 | 2013 | 2 | 0.420 |
Why?
| Gene Expression Regulation | 7 | 2009 | 2293 | 0.420 |
Why?
| Cell Line | 11 | 2014 | 2581 | 0.410 |
Why?
| Pseudomonas aeruginosa | 4 | 2016 | 297 | 0.400 |
Why?
| Humans | 78 | 2022 | 113531 | 0.400 |
Why?
| Lysine | 1 | 2014 | 240 | 0.400 |
Why?
| Protein Array Analysis | 2 | 2012 | 55 | 0.400 |
Why?
| Lubiprostone | 3 | 2022 | 9 | 0.380 |
Why?
| Inflammation | 3 | 2017 | 2444 | 0.370 |
Why?
| NF-kappa B | 4 | 2009 | 615 | 0.360 |
Why?
| Quinolones | 4 | 2022 | 97 | 0.350 |
Why?
| Respiratory System | 3 | 2022 | 137 | 0.350 |
Why?
| Ubiquitin Thiolesterase | 1 | 2010 | 35 | 0.340 |
Why?
| Gene Expression Regulation, Developmental | 2 | 2006 | 777 | 0.330 |
Why?
| Caveolin 1 | 1 | 2009 | 19 | 0.330 |
Why?
| Proteome | 4 | 2009 | 335 | 0.320 |
Why?
| Aspergillus fumigatus | 1 | 2008 | 19 | 0.310 |
Why?
| Estrogen Antagonists | 1 | 2008 | 39 | 0.310 |
Why?
| Endocytosis | 1 | 2009 | 143 | 0.310 |
Why?
| Dinoprostone | 3 | 2022 | 178 | 0.300 |
Why?
| Calcium | 3 | 2008 | 1086 | 0.300 |
Why?
| Trachea | 2 | 2008 | 220 | 0.300 |
Why?
| Adolescent | 31 | 2020 | 17724 | 0.300 |
Why?
| Tamoxifen | 1 | 2008 | 190 | 0.290 |
Why?
| Adult | 34 | 2022 | 30245 | 0.290 |
Why?
| Transcription Factor CHOP | 1 | 2007 | 28 | 0.290 |
Why?
| Levofloxacin | 1 | 2007 | 22 | 0.280 |
Why?
| Ofloxacin | 1 | 2007 | 22 | 0.280 |
Why?
| Drugs, Investigational | 1 | 2007 | 30 | 0.270 |
Why?
| S-Nitrosoglutathione | 1 | 2006 | 6 | 0.270 |
Why?
| Mutant Proteins | 1 | 2007 | 95 | 0.270 |
Why?
| Heparan Sulfate Proteoglycans | 1 | 2006 | 21 | 0.260 |
Why?
| Anti-Bacterial Agents | 6 | 2014 | 1465 | 0.260 |
Why?
| Nebulizers and Vaporizers | 2 | 2005 | 77 | 0.260 |
Why?
| Genetic Testing | 1 | 2008 | 381 | 0.260 |
Why?
| Pneumonia, Bacterial | 1 | 2007 | 102 | 0.260 |
Why?
| Membrane Potentials | 5 | 2013 | 246 | 0.260 |
Why?
| Sinusitis | 3 | 2020 | 174 | 0.250 |
Why?
| Chloride Channel Agonists | 2 | 2021 | 62 | 0.250 |
Why?
| Estradiol | 1 | 2008 | 450 | 0.250 |
Why?
| Water | 1 | 2008 | 394 | 0.250 |
Why?
| Aerosols | 2 | 2005 | 146 | 0.250 |
Why?
| Antibodies, Monoclonal | 1 | 2012 | 1236 | 0.250 |
Why?
| Respiratory Function Tests | 6 | 2021 | 517 | 0.250 |
Why?
| Proteins | 3 | 2012 | 890 | 0.250 |
Why?
| Positive-Pressure Respiration | 1 | 2005 | 67 | 0.240 |
Why?
| Homeostasis | 1 | 2008 | 561 | 0.240 |
Why?
| Pyrrolidines | 2 | 2022 | 55 | 0.230 |
Why?
| Female | 39 | 2020 | 59115 | 0.230 |
Why?
| Curcumin | 1 | 2004 | 28 | 0.230 |
Why?
| Flavonoids | 1 | 2004 | 66 | 0.220 |
Why?
| Male | 37 | 2020 | 55112 | 0.220 |
Why?
| Dose-Response Relationship, Drug | 8 | 2017 | 1822 | 0.220 |
Why?
| Membrane Proteins | 2 | 2006 | 1008 | 0.220 |
Why?
| Immunity, Innate | 1 | 2009 | 716 | 0.220 |
Why?
| Plicamycin | 1 | 2003 | 3 | 0.220 |
Why?
| Genetic Vectors | 5 | 2005 | 285 | 0.210 |
Why?
| Signal Transduction | 4 | 2022 | 4439 | 0.210 |
Why?
| Amniotic Fluid | 1 | 2003 | 64 | 0.210 |
Why?
| Forced Expiratory Volume | 6 | 2018 | 468 | 0.200 |
Why?
| Cell Cycle Proteins | 1 | 2006 | 543 | 0.200 |
Why?
| Nanoparticles | 3 | 2011 | 308 | 0.200 |
Why?
| Heterozygote | 2 | 2021 | 248 | 0.200 |
Why?
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2022 | 6 | 0.200 |
Why?
| Peptides, Cyclic | 1 | 2004 | 252 | 0.200 |
Why?
| Pyrazoles | 2 | 2022 | 361 | 0.190 |
Why?
| Prostaglandins | 1 | 2022 | 77 | 0.190 |
Why?
| Biological Transport | 3 | 2008 | 363 | 0.190 |
Why?
| Animals | 17 | 2022 | 31162 | 0.190 |
Why?
| Pyridines | 2 | 2022 | 417 | 0.190 |
Why?
| Child | 25 | 2022 | 18340 | 0.190 |
Why?
| Oxadiazoles | 2 | 2014 | 32 | 0.180 |
Why?
| Epithelial Sodium Channels | 1 | 2021 | 12 | 0.180 |
Why?
| Aminopyridines | 2 | 2021 | 81 | 0.180 |
Why?
| Mice | 10 | 2022 | 14679 | 0.180 |
Why?
| Quinolines | 1 | 2021 | 127 | 0.180 |
Why?
| Antibodies, Viral | 2 | 2003 | 519 | 0.180 |
Why?
| Protein Structure, Tertiary | 2 | 2014 | 786 | 0.170 |
Why?
| Tobramycin | 4 | 2014 | 46 | 0.170 |
Why?
| Protein Transport | 3 | 2014 | 386 | 0.170 |
Why?
| Double-Blind Method | 6 | 2017 | 1643 | 0.170 |
Why?
| Paranasal Sinuses | 1 | 2020 | 66 | 0.160 |
Why?
| Ergocalciferols | 2 | 2010 | 11 | 0.160 |
Why?
| Ataxia Telangiectasia | 2 | 2010 | 17 | 0.160 |
Why?
| Pulmonary Medicine | 2 | 2010 | 69 | 0.160 |
Why?
| Genotype | 6 | 2021 | 1733 | 0.160 |
Why?
| Immunoglobulin G | 1 | 2003 | 760 | 0.160 |
Why?
| Cyclic AMP | 3 | 2008 | 222 | 0.160 |
Why?
| Biomarkers | 4 | 2017 | 3389 | 0.150 |
Why?
| Administration, Intranasal | 4 | 2007 | 76 | 0.150 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2020 | 182 | 0.150 |
Why?
| Sweat | 4 | 2016 | 38 | 0.150 |
Why?
| Subcellular Fractions | 2 | 2008 | 76 | 0.150 |
Why?
| Administration, Inhalation | 8 | 2007 | 633 | 0.150 |
Why?
| Vitamins | 2 | 2010 | 150 | 0.150 |
Why?
| Cell Membrane | 2 | 2014 | 663 | 0.150 |
Why?
| Respiratory Tract Infections | 3 | 2008 | 320 | 0.140 |
Why?
| Lung Diseases | 1 | 2003 | 688 | 0.140 |
Why?
| Vitamin D Deficiency | 2 | 2010 | 158 | 0.140 |
Why?
| Mice, Knockout | 3 | 2009 | 2523 | 0.140 |
Why?
| Maryland | 1 | 2017 | 37 | 0.140 |
Why?
| Membrane Transport Modulators | 1 | 2017 | 6 | 0.140 |
Why?
| Aldehyde Oxidoreductases | 1 | 2017 | 29 | 0.140 |
Why?
| Rifampin | 1 | 2017 | 68 | 0.130 |
Why?
| DNA-Binding Proteins | 1 | 2003 | 1286 | 0.130 |
Why?
| Adenosine Triphosphate | 2 | 2008 | 426 | 0.130 |
Why?
| Leukocyte Count | 1 | 2017 | 291 | 0.130 |
Why?
| Young Adult | 9 | 2020 | 10400 | 0.130 |
Why?
| Computational Biology | 2 | 2012 | 527 | 0.130 |
Why?
| Child, Preschool | 11 | 2021 | 9093 | 0.130 |
Why?
| Transcription Factors | 1 | 2003 | 1497 | 0.120 |
Why?
| Drug Combinations | 3 | 2022 | 285 | 0.120 |
Why?
| Molecular Chaperones | 2 | 2008 | 156 | 0.120 |
Why?
| Gene Transfer Techniques | 3 | 2005 | 144 | 0.120 |
Why?
| Sleep | 1 | 2019 | 568 | 0.120 |
Why?
| Drug Design | 2 | 2007 | 146 | 0.120 |
Why?
| Cell Line, Transformed | 2 | 2006 | 132 | 0.110 |
Why?
| Protein Folding | 3 | 2004 | 239 | 0.110 |
Why?
| Sodium Chloride | 2 | 2005 | 132 | 0.110 |
Why?
| Ubiquitination | 1 | 2014 | 86 | 0.110 |
Why?
| Cells, Cultured | 4 | 2021 | 3802 | 0.110 |
Why?
| Aspergillosis, Allergic Bronchopulmonary | 2 | 2016 | 9 | 0.110 |
Why?
| Exocrine Pancreatic Insufficiency | 2 | 2016 | 17 | 0.110 |
Why?
| Protein Stability | 1 | 2014 | 156 | 0.110 |
Why?
| Amiloride | 2 | 2004 | 23 | 0.110 |
Why?
| Proteolysis | 1 | 2014 | 141 | 0.110 |
Why?
| Phenotype | 6 | 2016 | 2754 | 0.110 |
Why?
| Neutrophils | 2 | 2017 | 1072 | 0.110 |
Why?
| Pediatrics | 3 | 2010 | 981 | 0.110 |
Why?
| Mass Spectrometry | 2 | 2014 | 616 | 0.110 |
Why?
| Promoter Regions, Genetic | 3 | 2009 | 1110 | 0.110 |
Why?
| Isoproterenol | 2 | 2004 | 105 | 0.110 |
Why?
| Mice, Inbred C57BL | 3 | 2013 | 4617 | 0.100 |
Why?
| Electrophoresis, Gel, Two-Dimensional | 3 | 2009 | 94 | 0.100 |
Why?
| Colforsin | 2 | 2021 | 48 | 0.100 |
Why?
| HEK293 Cells | 1 | 2014 | 585 | 0.100 |
Why?
| Enzyme Inhibitors | 2 | 2006 | 737 | 0.100 |
Why?
| Age Factors | 2 | 2017 | 2875 | 0.100 |
Why?
| Down-Regulation | 3 | 2021 | 593 | 0.100 |
Why?
| RNA, Messenger | 3 | 2008 | 2507 | 0.090 |
Why?
| Expectorants | 1 | 2011 | 24 | 0.090 |
Why?
| Protein Conformation | 1 | 2014 | 798 | 0.090 |
Why?
| Staining and Labeling | 1 | 2012 | 133 | 0.090 |
Why?
| Research Personnel | 2 | 2010 | 147 | 0.090 |
Why?
| Transduction, Genetic | 1 | 2011 | 112 | 0.090 |
Why?
| Vital Capacity | 1 | 2011 | 249 | 0.090 |
Why?
| Acetylcysteine | 1 | 2011 | 141 | 0.090 |
Why?
| Microbiota | 1 | 2017 | 646 | 0.090 |
Why?
| Endopeptidases | 1 | 2010 | 70 | 0.090 |
Why?
| Cervix Mucus | 1 | 2009 | 1 | 0.080 |
Why?
| Anhydrides | 1 | 2009 | 18 | 0.080 |
Why?
| Models, Biological | 2 | 2007 | 1589 | 0.080 |
Why?
| Models, Molecular | 1 | 2014 | 1359 | 0.080 |
Why?
| Homozygote | 1 | 2010 | 186 | 0.080 |
Why?
| Membrane Microdomains | 1 | 2009 | 29 | 0.080 |
Why?
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2009 | 93 | 0.080 |
Why?
| Synaptosomes | 1 | 2009 | 12 | 0.080 |
Why?
| Posterior Horn Cells | 1 | 2009 | 4 | 0.080 |
Why?
| Spiperone | 1 | 2008 | 1 | 0.080 |
Why?
| Endoscopy | 1 | 2011 | 245 | 0.080 |
Why?
| Ribosomes | 1 | 2010 | 146 | 0.080 |
Why?
| Rats | 3 | 2009 | 4829 | 0.080 |
Why?
| Microscopy, Confocal | 1 | 2010 | 292 | 0.080 |
Why?
| Drug Carriers | 1 | 2009 | 110 | 0.080 |
Why?
| Nutrition Assessment | 1 | 2009 | 75 | 0.080 |
Why?
| Electric Conductivity | 1 | 2008 | 87 | 0.080 |
Why?
| Polyethylene Glycols | 2 | 2011 | 557 | 0.080 |
Why?
| Respiratory System Agents | 1 | 2008 | 22 | 0.080 |
Why?
| Malnutrition | 1 | 2009 | 62 | 0.080 |
Why?
| Administration, Topical | 1 | 2008 | 137 | 0.080 |
Why?
| Treatment Outcome | 9 | 2018 | 9006 | 0.080 |
Why?
| Biopsy | 1 | 2012 | 1024 | 0.080 |
Why?
| Mice, Transgenic | 1 | 2013 | 1925 | 0.070 |
Why?
| Codon, Terminator | 2 | 2007 | 21 | 0.070 |
Why?
| Blotting, Western | 2 | 2007 | 1128 | 0.070 |
Why?
| Fibrous Dysplasia, Polyostotic | 1 | 2007 | 7 | 0.070 |
Why?
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2007 | 8 | 0.070 |
Why?
| Statistics, Nonparametric | 2 | 2005 | 384 | 0.070 |
Why?
| Adenoviridae | 2 | 2005 | 179 | 0.070 |
Why?
| Cytosol | 1 | 2008 | 199 | 0.070 |
Why?
| Socioeconomic Factors | 1 | 2011 | 1080 | 0.070 |
Why?
| Aminoglycosides | 1 | 2007 | 13 | 0.070 |
Why?
| Chromatin Immunoprecipitation | 1 | 2007 | 126 | 0.070 |
Why?
| Ibuprofen | 1 | 2007 | 75 | 0.070 |
Why?
| Technology, Pharmaceutical | 1 | 2007 | 18 | 0.070 |
Why?
| Metabolic Clearance Rate | 1 | 2007 | 103 | 0.070 |
Why?
| Mannose-Binding Lectin | 1 | 2006 | 19 | 0.070 |
Why?
| Nutritional Status | 1 | 2009 | 286 | 0.070 |
Why?
| Cyclooxygenase 2 | 1 | 2007 | 161 | 0.070 |
Why?
| Asthma | 1 | 2019 | 2016 | 0.070 |
Why?
| Airway Obstruction | 1 | 2008 | 158 | 0.070 |
Why?
| Kidney Function Tests | 1 | 2007 | 139 | 0.070 |
Why?
| HSP40 Heat-Shock Proteins | 1 | 2006 | 21 | 0.070 |
Why?
| Valosin Containing Protein | 1 | 2006 | 6 | 0.070 |
Why?
| Polysaccharide-Lyases | 1 | 2006 | 11 | 0.070 |
Why?
| DNA Primers | 1 | 2007 | 496 | 0.070 |
Why?
| DNA, Viral | 2 | 2005 | 345 | 0.070 |
Why?
| Tunicamycin | 1 | 2006 | 11 | 0.070 |
Why?
| Proteasome Inhibitors | 1 | 2006 | 41 | 0.070 |
Why?
| CHO Cells | 1 | 2006 | 135 | 0.060 |
Why?
| Chondroitin Sulfates | 1 | 2006 | 33 | 0.060 |
Why?
| Spinal Cord Injuries | 1 | 2009 | 171 | 0.060 |
Why?
| Technetium Tc 99m Pentetate | 1 | 2005 | 7 | 0.060 |
Why?
| Gamma Cameras | 1 | 2005 | 7 | 0.060 |
Why?
| Cricetinae | 1 | 2006 | 244 | 0.060 |
Why?
| Luciferases | 2 | 2003 | 139 | 0.060 |
Why?
| Radionuclide Imaging | 1 | 2005 | 115 | 0.060 |
Why?
| Glycosylation | 1 | 2006 | 128 | 0.060 |
Why?
| Precision Medicine | 1 | 2009 | 335 | 0.060 |
Why?
| Nitric Oxide Synthase | 1 | 2006 | 209 | 0.060 |
Why?
| Glutamine | 1 | 2006 | 90 | 0.060 |
Why?
| Chronic Disease | 2 | 2008 | 1570 | 0.060 |
Why?
| Purinergic P2 Receptor Agonists | 1 | 2005 | 4 | 0.060 |
Why?
| Adenosine Triphosphatases | 1 | 2006 | 152 | 0.060 |
Why?
| Nerve Tissue Proteins | 1 | 2009 | 521 | 0.060 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 914 | 0.060 |
Why?
| Deoxycytosine Nucleotides | 1 | 2005 | 11 | 0.060 |
Why?
| Uridine | 1 | 2005 | 28 | 0.060 |
Why?
| Tissue Distribution | 1 | 2005 | 280 | 0.060 |
Why?
| Gene Expression Profiling | 3 | 2006 | 1510 | 0.060 |
Why?
| Polymers | 1 | 2009 | 448 | 0.060 |
Why?
| Radiopharmaceuticals | 1 | 2005 | 158 | 0.060 |
Why?
| Acidosis | 1 | 2006 | 85 | 0.060 |
Why?
| DNA | 1 | 2011 | 1331 | 0.060 |
Why?
| Particle Size | 1 | 2005 | 310 | 0.060 |
Why?
| Dietary Supplements | 1 | 2008 | 459 | 0.060 |
Why?
| Nasal Polyps | 1 | 2004 | 49 | 0.060 |
Why?
| Biomedical Research | 1 | 2010 | 581 | 0.060 |
Why?
| Inhalation Exposure | 1 | 2004 | 95 | 0.060 |
Why?
| Transfection | 1 | 2006 | 842 | 0.050 |
Why?
| Base Sequence | 1 | 2007 | 2080 | 0.050 |
Why?
| Drug Administration Schedule | 4 | 2010 | 712 | 0.050 |
Why?
| Bronchial Provocation Tests | 1 | 2003 | 46 | 0.050 |
Why?
| Recombinant Fusion Proteins | 2 | 2003 | 599 | 0.050 |
Why?
| Sex Factors | 1 | 2008 | 1705 | 0.050 |
Why?
| Sp3 Transcription Factor | 1 | 2003 | 6 | 0.050 |
Why?
| Disease Progression | 3 | 2017 | 2364 | 0.050 |
Why?
| Heat-Shock Proteins | 1 | 2004 | 112 | 0.050 |
Why?
| Diuretics | 1 | 2003 | 64 | 0.050 |
Why?
| Single-Blind Method | 1 | 2004 | 255 | 0.050 |
Why?
| RNA Interference | 1 | 2005 | 426 | 0.050 |
Why?
| Genetic Predisposition to Disease | 2 | 2008 | 2077 | 0.050 |
Why?
| Protein Denaturation | 1 | 2003 | 67 | 0.050 |
Why?
| Clinical Protocols | 1 | 2004 | 231 | 0.050 |
Why?
| 5' Flanking Region | 1 | 2002 | 8 | 0.050 |
Why?
| Clinical Trials as Topic | 2 | 2004 | 922 | 0.050 |
Why?
| Biological Transport, Active | 1 | 2002 | 71 | 0.050 |
Why?
| Tetradecanoylphorbol Acetate | 1 | 2002 | 145 | 0.050 |
Why?
| Carrier State | 1 | 2002 | 54 | 0.050 |
Why?
| Patient Acceptance of Health Care | 1 | 2008 | 679 | 0.050 |
Why?
| Infant | 4 | 2020 | 7922 | 0.050 |
Why?
| Dimethyl Sulfoxide | 1 | 2022 | 41 | 0.050 |
Why?
| Forecasting | 1 | 2003 | 329 | 0.050 |
Why?
| 1-Methyl-3-isobutylxanthine | 1 | 2021 | 23 | 0.050 |
Why?
| Anesthesiologists | 1 | 2022 | 11 | 0.050 |
Why?
| Middle Aged | 8 | 2020 | 26552 | 0.050 |
Why?
| Protein Isoforms | 1 | 2003 | 324 | 0.050 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2006 | 1106 | 0.050 |
Why?
| Occupational Exposure | 1 | 2004 | 254 | 0.050 |
Why?
| Interleukin-13 | 1 | 2022 | 121 | 0.050 |
Why?
| Interferon-gamma | 1 | 2005 | 710 | 0.050 |
Why?
| Bronchodilator Agents | 1 | 2003 | 238 | 0.050 |
Why?
| Point Mutation | 1 | 2002 | 214 | 0.050 |
Why?
| Genetic Variation | 1 | 2006 | 854 | 0.050 |
Why?
| NIH 3T3 Cells | 1 | 2021 | 137 | 0.050 |
Why?
| Drug Therapy, Combination | 1 | 2004 | 944 | 0.050 |
Why?
| Electrophysiology | 1 | 2021 | 198 | 0.050 |
Why?
| Nitric Oxide | 1 | 2006 | 814 | 0.050 |
Why?
| Up-Regulation | 1 | 2004 | 794 | 0.050 |
Why?
| Anti-Infective Agents | 1 | 2003 | 218 | 0.050 |
Why?
| Codon, Nonsense | 2 | 2014 | 37 | 0.050 |
Why?
| Respiration | 1 | 2021 | 168 | 0.040 |
Why?
| Drug Monitoring | 2 | 2017 | 184 | 0.040 |
Why?
| Nasal Surgical Procedures | 1 | 2020 | 5 | 0.040 |
Why?
| Patient Care Team | 1 | 2004 | 518 | 0.040 |
Why?
| Viscosity | 2 | 2011 | 81 | 0.040 |
Why?
| Transcription, Genetic | 1 | 2006 | 1282 | 0.040 |
Why?
| Cell Survival | 1 | 2003 | 1004 | 0.040 |
Why?
| Bronchoalveolar Lavage Fluid | 2 | 2017 | 578 | 0.040 |
Why?
| Retrospective Studies | 5 | 2020 | 12504 | 0.040 |
Why?
| Longitudinal Studies | 2 | 2018 | 2361 | 0.040 |
Why?
| Albuterol | 1 | 2019 | 101 | 0.040 |
Why?
| Spirometry | 1 | 2019 | 220 | 0.040 |
Why?
| Biological Products | 1 | 2021 | 166 | 0.040 |
Why?
| Immunohistochemistry | 1 | 2003 | 1604 | 0.040 |
Why?
| Haplotypes | 1 | 2020 | 443 | 0.040 |
Why?
| Temperature | 1 | 2021 | 557 | 0.040 |
Why?
| Cross-Over Studies | 1 | 2019 | 432 | 0.040 |
Why?
| Bacteria | 1 | 2003 | 716 | 0.040 |
Why?
| Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 5 | 0.040 |
Why?
| Seasons | 2 | 2010 | 437 | 0.030 |
Why?
| Fellowships and Scholarships | 2 | 2010 | 224 | 0.030 |
Why?
| Biological Availability | 1 | 2017 | 119 | 0.030 |
Why?
| Biphenyl Compounds | 1 | 2017 | 50 | 0.030 |
Why?
| DNA, Bacterial | 1 | 2017 | 308 | 0.030 |
Why?
| Cell Differentiation | 1 | 2003 | 1681 | 0.030 |
Why?
| Pharmacogenetics | 1 | 2017 | 149 | 0.030 |
Why?
| Drug Interactions | 1 | 2017 | 332 | 0.030 |
Why?
| Case-Control Studies | 2 | 2017 | 2993 | 0.030 |
Why?
| China | 1 | 2016 | 161 | 0.030 |
Why?
| 3' Untranslated Regions | 1 | 2016 | 129 | 0.030 |
Why?
| Regression Analysis | 1 | 2017 | 932 | 0.030 |
Why?
| Exons | 1 | 2016 | 300 | 0.030 |
Why?
| Bronchiectasis | 1 | 2016 | 105 | 0.030 |
Why?
| Antineoplastic Agents | 1 | 2005 | 1872 | 0.030 |
Why?
| Time Factors | 3 | 2010 | 6032 | 0.030 |
Why?
| Colony Count, Microbial | 2 | 2005 | 109 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2017 | 1421 | 0.030 |
Why?
| Polymerase Chain Reaction | 2 | 2007 | 984 | 0.030 |
Why?
| Aging | 1 | 2003 | 1601 | 0.030 |
Why?
| Prevalence | 2 | 2010 | 2244 | 0.030 |
Why?
| Genes, Reporter | 2 | 2005 | 248 | 0.030 |
Why?
| Polylysine | 1 | 2011 | 17 | 0.020 |
Why?
| Biopolymers | 1 | 2011 | 26 | 0.020 |
Why?
| Pregnancy | 1 | 2003 | 5490 | 0.020 |
Why?
| Follow-Up Studies | 2 | 2010 | 4384 | 0.020 |
Why?
| Diffusion | 1 | 2011 | 115 | 0.020 |
Why?
| Mucins | 1 | 2011 | 61 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2020 | 2269 | 0.020 |
Why?
| Cross-Sectional Studies | 2 | 2011 | 4400 | 0.020 |
Why?
| Plasmids | 1 | 2011 | 334 | 0.020 |
Why?
| CD4-CD8 Ratio | 1 | 2010 | 19 | 0.020 |
Why?
| 25-Hydroxyvitamin D 2 | 1 | 2010 | 7 | 0.020 |
Why?
| alpha-Fetoproteins | 1 | 2010 | 31 | 0.020 |
Why?
| Calcifediol | 1 | 2010 | 29 | 0.020 |
Why?
| Accreditation | 1 | 2010 | 76 | 0.020 |
Why?
| Immunoassay | 1 | 2010 | 94 | 0.020 |
Why?
| Cohort Studies | 2 | 2011 | 4880 | 0.020 |
Why?
| Societies, Scientific | 1 | 2009 | 46 | 0.020 |
Why?
| Indicator Dilution Techniques | 1 | 2009 | 9 | 0.020 |
Why?
| Adhesiveness | 1 | 2009 | 19 | 0.020 |
Why?
| Mice, Inbred CFTR | 1 | 2008 | 5 | 0.020 |
Why?
| Quality of Life | 1 | 2019 | 2335 | 0.020 |
Why?
| Type C Phospholipases | 1 | 2008 | 64 | 0.020 |
Why?
| Biological Assay | 1 | 2008 | 112 | 0.020 |
Why?
| Baltimore | 1 | 2008 | 43 | 0.020 |
Why?
| Small Molecule Libraries | 1 | 2008 | 79 | 0.020 |
Why?
| Cell Polarity | 1 | 2008 | 127 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2010 | 360 | 0.020 |
Why?
| Drug Discovery | 1 | 2008 | 122 | 0.020 |
Why?
| Career Choice | 1 | 2009 | 177 | 0.020 |
Why?
| Prospective Studies | 1 | 2018 | 6189 | 0.020 |
Why?
| Hospitals, University | 1 | 2008 | 169 | 0.020 |
Why?
| Acute Kidney Injury | 1 | 2014 | 676 | 0.020 |
Why?
| Models, Animal | 1 | 2009 | 337 | 0.020 |
Why?
| Receptors, Cell Surface | 1 | 2009 | 347 | 0.020 |
Why?
| Placebos | 1 | 2007 | 198 | 0.020 |
Why?
| Solutions | 1 | 2007 | 142 | 0.020 |
Why?
| Gentamicins | 1 | 2007 | 42 | 0.020 |
Why?
| Nutrition Surveys | 1 | 2008 | 225 | 0.020 |
Why?
| Comorbidity | 1 | 2011 | 1443 | 0.020 |
Why?
| Sulfur Radioisotopes | 1 | 2006 | 16 | 0.020 |
Why?
| Silver Staining | 1 | 2006 | 17 | 0.020 |
Why?
| Energy Intake | 1 | 2009 | 424 | 0.020 |
Why?
| Dual Oxidases | 1 | 2006 | 1 | 0.020 |
Why?
| Flavoproteins | 1 | 2006 | 7 | 0.020 |
Why?
| Salivary Proteins and Peptides | 1 | 2006 | 10 | 0.020 |
Why?
| Peptide Mapping | 1 | 2006 | 59 | 0.020 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2006 | 131 | 0.020 |
Why?
| Health Care Surveys | 1 | 2008 | 541 | 0.020 |
Why?
| Education, Medical, Graduate | 1 | 2010 | 366 | 0.020 |
Why?
| NADPH Oxidases | 1 | 2006 | 96 | 0.020 |
Why?
| Societies, Medical | 1 | 2009 | 654 | 0.020 |
Why?
| Severity of Illness Index | 2 | 2004 | 2530 | 0.020 |
Why?
| Cell Membrane Permeability | 1 | 2006 | 81 | 0.020 |
Why?
| Methionine | 1 | 2006 | 144 | 0.020 |
Why?
| Blotting, Southern | 1 | 2005 | 67 | 0.020 |
Why?
| Serum | 1 | 2006 | 57 | 0.020 |
Why?
| Receptors, Purinergic P2Y2 | 1 | 2005 | 5 | 0.020 |
Why?
| Protein-Tyrosine Kinases | 1 | 2008 | 390 | 0.020 |
Why?
| Helper Viruses | 1 | 2005 | 2 | 0.020 |
Why?
| Nasal Cavity | 1 | 2005 | 46 | 0.020 |
Why?
| Burkholderia | 1 | 2005 | 13 | 0.020 |
Why?
| Pancreatic Elastase | 1 | 2005 | 55 | 0.020 |
Why?
| Hemoptysis | 1 | 2005 | 33 | 0.010 |
Why?
| Peroxidase | 1 | 2005 | 160 | 0.010 |
Why?
| Hydrogen-Ion Concentration | 1 | 2006 | 502 | 0.010 |
Why?
| Quality of Health Care | 1 | 2009 | 572 | 0.010 |
Why?
| Kaplan-Meier Estimate | 1 | 2006 | 809 | 0.010 |
Why?
| Reference Values | 1 | 2006 | 735 | 0.010 |
Why?
| Reagent Kits, Diagnostic | 1 | 2004 | 42 | 0.010 |
Why?
| Rats, Sprague-Dawley | 1 | 2009 | 2139 | 0.010 |
Why?
| Syndrome | 1 | 2004 | 328 | 0.010 |
Why?
| Antibodies | 1 | 2006 | 354 | 0.010 |
Why?
| Siblings | 1 | 2004 | 215 | 0.010 |
Why?
| Proportional Hazards Models | 1 | 2006 | 1076 | 0.010 |
Why?
| Treatment Failure | 1 | 2004 | 323 | 0.010 |
Why?
| United States | 2 | 2010 | 12137 | 0.010 |
Why?
| DNA, Recombinant | 1 | 2003 | 40 | 0.010 |
Why?
| Survivors | 1 | 2006 | 414 | 0.010 |
Why?
| Survival Analysis | 1 | 2006 | 1203 | 0.010 |
Why?
| Heating | 1 | 2003 | 17 | 0.010 |
Why?
| Saline Solution, Hypertonic | 1 | 2003 | 39 | 0.010 |
Why?
| Virus Shedding | 1 | 2003 | 39 | 0.010 |
Why?
| Logistic Models | 1 | 2008 | 1832 | 0.010 |
Why?
| Dyspnea | 1 | 2005 | 211 | 0.010 |
Why?
| Probability | 1 | 2004 | 285 | 0.010 |
Why?
| Hearing Disorders | 1 | 2002 | 9 | 0.010 |
Why?
| Bronchoscopy | 1 | 2004 | 193 | 0.010 |
Why?
| Oxidative Stress | 1 | 2009 | 1065 | 0.010 |
Why?
| Audiometry | 1 | 2002 | 25 | 0.010 |
Why?
| Oropharynx | 1 | 2002 | 36 | 0.010 |
Why?
| Confidence Intervals | 1 | 2003 | 302 | 0.010 |
Why?
| Electrophoresis, Gel, Pulsed-Field | 1 | 2002 | 17 | 0.010 |
Why?
| Viremia | 1 | 2003 | 122 | 0.010 |
Why?
| Infusions, Intravenous | 1 | 2003 | 368 | 0.010 |
Why?
| Prognosis | 1 | 2010 | 3318 | 0.010 |
Why?
| Recurrence | 1 | 2004 | 925 | 0.010 |
Why?
| Body Mass Index | 1 | 2009 | 1952 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2005 | 1214 | 0.010 |
Why?
| Genetic Linkage | 1 | 2002 | 289 | 0.010 |
Why?
| Gene Rearrangement | 1 | 2002 | 135 | 0.010 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 739 | 0.010 |
Why?
| Interleukins | 1 | 2003 | 234 | 0.010 |
Why?
| Pedigree | 1 | 2002 | 460 | 0.010 |
Why?
| DNA Mutational Analysis | 1 | 2002 | 372 | 0.010 |
Why?
| Feasibility Studies | 1 | 2004 | 737 | 0.010 |
Why?
| Chi-Square Distribution | 1 | 2002 | 493 | 0.010 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 783 | 0.010 |
Why?
| Interleukin-6 | 1 | 2005 | 661 | 0.010 |
Why?
| Gene Expression | 1 | 2006 | 1397 | 0.010 |
Why?
| Sensitivity and Specificity | 1 | 2005 | 1682 | 0.010 |
Why?
| Analysis of Variance | 1 | 2004 | 1208 | 0.010 |
Why?
| Creatinine | 1 | 2002 | 434 | 0.010 |
Why?
| Safety | 1 | 2002 | 297 | 0.010 |
Why?
| Tumor Cells, Cultured | 1 | 2002 | 834 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2008 | 2752 | 0.010 |
Why?
| Kinetics | 1 | 2004 | 1528 | 0.010 |
Why?
| Apoptosis | 1 | 2009 | 2288 | 0.010 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 1168 | 0.010 |
Why?
| Disease Models, Animal | 1 | 2008 | 3470 | 0.010 |
Why?
| Kidney Diseases | 1 | 2002 | 348 | 0.010 |
Why?
| Surveys and Questionnaires | 1 | 2010 | 4593 | 0.010 |
Why?
| Infant, Newborn | 1 | 2008 | 5032 | 0.010 |
Why?
| Cytokines | 1 | 2005 | 1795 | 0.010 |
Why?
| Hospitalization | 1 | 2005 | 1765 | 0.010 |
Why?
| Adenocarcinoma | 1 | 2002 | 787 | 0.010 |
Why?
| Risk Factors | 1 | 2008 | 8606 | 0.010 |
Why?
| Risk Assessment | 1 | 2004 | 2953 | 0.010 |
Why?
| Lung Neoplasms | 1 | 2002 | 2148 | 0.010 |
Why?
|
|
Zeitlin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|